Lurbinectedin-induced thrombocytopenia: the role of body surface area

Lurbinectedin is an alkylating agent approved for the second-line treatment of small cell lung cancer. Although initial studies showed no association between body surface area (BSA) and drug clearance, the recommended dose is 3.2 mg/m(2) every 3 weeks. This recommendation was based on an exposure–re...

Descripción completa

Detalles Bibliográficos
Autores principales: Papachristos, Apostolos, Ratain, Mark J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8972734/
https://www.ncbi.nlm.nih.gov/pubmed/35362793
http://dx.doi.org/10.1007/s00280-022-04422-6
_version_ 1784679910957121536
author Papachristos, Apostolos
Ratain, Mark J.
author_facet Papachristos, Apostolos
Ratain, Mark J.
author_sort Papachristos, Apostolos
collection PubMed
description Lurbinectedin is an alkylating agent approved for the second-line treatment of small cell lung cancer. Although initial studies showed no association between body surface area (BSA) and drug clearance, the recommended dose is 3.2 mg/m(2) every 3 weeks. This recommendation was based on an exposure–response study, which demonstrated that patients with lower BSA had a higher incidence of thrombocytopenia. Herein we present the factors associated with BSA and thrombopoiesis, which may have contributed to the observed relationship.
format Online
Article
Text
id pubmed-8972734
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-89727342022-04-01 Lurbinectedin-induced thrombocytopenia: the role of body surface area Papachristos, Apostolos Ratain, Mark J. Cancer Chemother Pharmacol Editorial Lurbinectedin is an alkylating agent approved for the second-line treatment of small cell lung cancer. Although initial studies showed no association between body surface area (BSA) and drug clearance, the recommended dose is 3.2 mg/m(2) every 3 weeks. This recommendation was based on an exposure–response study, which demonstrated that patients with lower BSA had a higher incidence of thrombocytopenia. Herein we present the factors associated with BSA and thrombopoiesis, which may have contributed to the observed relationship. Springer Berlin Heidelberg 2022-04-01 2022 /pmc/articles/PMC8972734/ /pubmed/35362793 http://dx.doi.org/10.1007/s00280-022-04422-6 Text en © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Editorial
Papachristos, Apostolos
Ratain, Mark J.
Lurbinectedin-induced thrombocytopenia: the role of body surface area
title Lurbinectedin-induced thrombocytopenia: the role of body surface area
title_full Lurbinectedin-induced thrombocytopenia: the role of body surface area
title_fullStr Lurbinectedin-induced thrombocytopenia: the role of body surface area
title_full_unstemmed Lurbinectedin-induced thrombocytopenia: the role of body surface area
title_short Lurbinectedin-induced thrombocytopenia: the role of body surface area
title_sort lurbinectedin-induced thrombocytopenia: the role of body surface area
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8972734/
https://www.ncbi.nlm.nih.gov/pubmed/35362793
http://dx.doi.org/10.1007/s00280-022-04422-6
work_keys_str_mv AT papachristosapostolos lurbinectedininducedthrombocytopeniatheroleofbodysurfacearea
AT ratainmarkj lurbinectedininducedthrombocytopeniatheroleofbodysurfacearea

Ejemplares similares